Show simple item record

dc.contributor.authorLópez Janeiro, Álvaro
dc.contributor.authorVillalba Esparza, María
dc.contributor.authorBrizzi, María Emilia
dc.contributor.authorJiménez Sánchez, Daniel
dc.contributor.authorRuz Caracuel, Ignacio
dc.contributor.authorKadioglu, Ece
dc.contributor.authorMasetto, Ivan
dc.contributor.authorGoubert, Virginie
dc.contributor.authorGarcia Ros, David
dc.contributor.authorMelero, Ignacio
dc.contributor.authorPeláez García, Alberto
dc.contributor.authorHardisson Hernáez, David Alonso 
dc.contributor.authorde Andrea, Carlos E.
dc.contributor.otherUAM. Departamento de Anatomía Patológicaes_ES
dc.date.accessioned2022-11-30T11:10:50Z
dc.date.available2022-11-30T11:10:50Z
dc.date.issued2022-10-25
dc.identifier.citationThe Journal of Pathology 258.4 (2022): 426-436en_US
dc.identifier.issn0022-3417 (print)en_US
dc.identifier.issn1096-9896 (online)en_US
dc.identifier.urihttp://hdl.handle.net/10486/705422
dc.description.abstractEndometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low-grade, early-stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out tomeasure CD8, CD68, FOXP3, PD-1,and PD-L1markers, aswell as cytokeratin (CK), on tissuemicroarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering.Most samples (69%) belonged to theimmune-desert subtype, characterized by lowimmune cell densities. Tumor-infiltrating lymphocyte (TIL)-rich samples (4%) displayed high CD8+ T-cell infiltration, as well as a high percentage of CD8/PD-1+ cells. Immune-exclusion samples (19%) displayed the lowest CD8+ infiltration combined with high PD-L1 expression levels in CK+ tumor cells. In addition, they demonstrated high tumor cell spatial clustering as well as increased spatial proximity of CD8+/PD-1+ andCK/PD-L1+ cells.FOXP3andmacrophage-rich phenotypes (3%and 4% of total samples) displayed relatively high levels of FOXP3+ regulatory T-cells and CD68+ macrophages, respectively. These phenotypes correlated with clinical outcomes, with immune-exclusion tumors showing an association with tumor relapse. When compared with prediction models built using routine pathological variables, models optimized with immune variables showed increased outcome prediction capacity (AUC = 0.89 versus 0.78) and stratification potential. The improved prediction capacity was independent of mismatch repair protein status and adjuvant radiotherapy treatment. Further, immunofluorescence results could be partially recapitulated using single-marker immunohistochemistry (IHC) performed on whole tissue sections. TIL-rich tumors demonstrated increased CD8+ T-cells by IHC, while immune-exclusion tumors displayed a lack of CD8+ T-cells and frequent expression of PD-L1 in tumor cells. Our results demonstrate the capability of the immune microenvironment to improve standard prediction tools in low-grade, early-stage endometrial carcinomasen_US
dc.description.sponsorshipCEA and IgM were funded by Fundación La Marató de TV3. This project was supported by grants from Partners of Choice Network from AstraZeneca and by the Instituto de Salud Carlos III (ISCIII) (PI17/01723 and PI21/00920), co-financed by the European Regional Development Fund ‘A way to achieve Europe’ (FEDER). We thank Marco Cassano (Lunaphore Technologies) for his help in writing the manuscripten_US
dc.format.extent11 pag.es_ES
dc.format.mimetypeapplication/pdfen_US
dc.language.isoengen
dc.publisherWileyen_US
dc.relation.ispartofJournal of Pathologyen_US
dc.rights© 2022 The Authorsen_US
dc.subject.otherClinical outcomeen_US
dc.subject.otherEndometrial canceren_US
dc.subject.otherImmune microenvironmenten_US
dc.subject.otherLow gradeen_US
dc.subject.otherMultiplex quantitative immunofluorescenceen_US
dc.subject.otherPrognosisen_US
dc.titleThe association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patientsen_US
dc.typearticleen_US
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttps://doi.org/10.1002/path.6012en_US
dc.identifier.doi10.1002/path.6012en_US
dc.identifier.publicationfirstpage426es_ES
dc.identifier.publicationissue4es_ES
dc.identifier.publicationlastpage436es_ES
dc.identifier.publicationvolume258es_ES
dc.relation.projectIDGobierno de España. PI17/01723es_ES
dc.relation.projectIDGobierno de España. PI21/00920es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen_US
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen_US
dc.facultadUAMFacultad de Medicinaes_ES
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record